March 15 Catalyst Pharmaceuticals Inc
said on Wednesday its experimental drug to treat patients with a
severe form of myasthenia gravis (MG), a rare neuromuscular
disease, met the main goals of a study.
The drug, Firdapse, was being tested on seven patients with
Musk-MG, a rare subpopulation of MG patients. There are
currently no FDA approved therapies for this form of MG.
Catalyst's shares jumped about 20 percent to $1.40 before
the bell on Wednesday.
(Reporting by Divya Grover in Bengaluru; Editing by Savio